Conditions: Peanut Allergy
Keywords: peanut allergy Xolair
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 13
Healthy volunteers: no

Brief summary:
This is a pilot feasibility study, using Xolair pretreatment for oral peanut desensitization.

Detailed description:
We hypothesize that pretreatment with anti-IgE mAb will greatly reduce the side effects and allergic reactions that occur during oral desensitization to peanut and will enhance the development of oral tolerance in patients with severe peanut allergy.

We will follow the patients for 5 years following study completion.

Arms:
arm 1: Patients receive omalizumab along with oral peanut desensitization.

Interventions: intervention 1: Omalizumab
Intervention descriptions: intervention 1: Omalizumab is an antibody that helps decrease allergic responses in the body

Protocol document: